(Q37206976)

English

Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register

scientific article published on 08 April 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register (English)

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

0 references

0 references

psoriatic arthritis

1 reference

based on heuristic

inferred from title

Darren M. Ashcroft

object named as

Darren M Ashcroft

2

0 references

Kimme L. Hyrich

4

object named as

Kimme L Hyrich

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Deborah P.M. Symmons

6

object named as

Deborah P M Symmons

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

author name string

Amr A Saad

1

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Kath D Watson

3

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Peter R Noyce

5

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

British Society for Rheumatology Biologics Register

7

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

publication date

8 April 2009

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Arthritis Research and Therapy

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

11

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

2

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

R52

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

https://scigraph.springernature.com/pub.10.1186/ar2670

0 references

Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2688203

6 September 2017

Medication compliance and persistence: terminology and definitions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2688203

6 September 2017

Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2688203

6 September 2017

The comparative effectiveness of anti-TNF therapy and methotrexate in patients with psoriatic arthritis: 6 month results from a longitudinal, observational, multicentre study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2688203

6 September 2017

Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2688203

6 September 2017

Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2688203

6 September 2017

Guideline for anti-TNF-alpha therapy in psoriatic arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2688203

6 September 2017

Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2688203

6 September 2017

Appraisal of the MedDRA conceptual structure for describing and grouping adverse drug reactions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2688203

6 September 2017

British Society for Rheumatology Biologics Register

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2688203

6 September 2017

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2688203

6 September 2017

Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2688203

26 June 2018

Channeling bias in the interpretation of drug effects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2688203

26 June 2018

Comparison of 4 functional indexes in psoriatic arthritis with axial or peripheral disease subgroups using Rasch analyses.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2688203

3 September 2018

Sustained response to long-term biologics and switching in psoriatic arthritis: results from real life experience.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2688203

3 September 2018

Outcomes after switching from one anti–tumor necrosis factor α agent to a second anti–tumor necrosis factor α agent in patients with rheumatoid arthritis: Results from a large UK national cohort study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2688203

4 December 2018

Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)

1 reference

https://pubmed.ncbi.nlm.nih.gov/19356232

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/19356232

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Retention rates of tumor necrosis factor blockers in daily practice in 770 rheumatic patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/19356232

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study

1 reference

https://pubmed.ncbi.nlm.nih.gov/19356232

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pathogenesis of psoriatic arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19356232

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/19356232

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression

1 reference

https://pubmed.ncbi.nlm.nih.gov/19356232

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Measurement of patient outcome in arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19356232

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

STANFORD HEALTH ASSESSMENT QUESTIONNAIRE MODIFIED TO ASSESS DISABILITY IN BRITISH PATIENTS WITH RHEUMATOID ARTHRITIS

1 reference

https://pubmed.ncbi.nlm.nih.gov/19356232

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Measuring health status in psoriatic arthritis: the Health Assessment Questionnaire and its modification

1 reference

https://pubmed.ncbi.nlm.nih.gov/19356232

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Responsiveness of health status instruments to changes in articular status and perceived health in patients with psoriatic arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19356232

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37206976&oldid=1503856335"